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Abstract
Background: The proto-oncogene Src is an important non-receptor protein tyrosine kinase involved in signaling 
pathways that control cell adhesion, growth, migration and differentiation. It negatively regulates osteoblast activity, 
and, as such, its inhibition is a potential means to prevent bone loss. Dasatinib is a new dual Src/Bcr-Abl tyrosine kinase 
inhibitor initially developed for the treatment of chronic myeloid leukemia. It has also shown promising results in 
preclinical studies in various solid tumors. However, its effects on the differentiation of human osteoblasts have never 
been examined.
Methods: We evaluated the effects of dasatinib on bone marrow-derived mesenchymal stromal cells (MSC) 
differentiation into osteoblasts, in the presence or absence of a mixture of dexamethasone, ascorbic acid and β-
glycerophosphate (DAG) for up to 21 days. The differentiation kinetics was assessed by evaluating mineralization of the 
extracellular matrix, alkaline phosphatase (ALP) activity, and expression of osteoblastic markers (receptor activator of 
nuclear factor kappa B ligand [RANKL], bone sialoprotein [BSP], osteopontin [OPN]).
Results: Dasatinib significantly increased the activity of ALP and the level of calcium deposition in MSC cultured with 
DAG after, respectively, 7 and 14 days; it upregulated the expression of BSP and OPN genes independently of DAG; and 
it markedly downregulated the expression of RANKL gene and protein (decrease in RANKL/OPG ratio), the key factor 
that stimulates osteoclast differentiation and activity.
Conclusions: Our results suggest a dual role for dasatinib in both (i) stimulating osteoblast differentiation leading to a 
direct increase in bone formation, and (ii) downregulating RANKL synthesis by osteoblasts leading to an indirect 
inhibition of osteoclastogenesis. Thus, dasatinib is a potentially interesting candidate drug for the treatment of 
osteolysis through its dual effect on bone metabolism.
Background
Osteoblasts originate from mesenchymal osteoprogeni-
tor cells and play a key role in physiological bone turn-
over and pathological disorders including osteoporosis
[1], Paget's disease [2] and tumor-induced osteolysis [3].
Osteoblast functions are dependent on their differentia-
tion status. Indeed, immature osteoblasts regulate
recruitment, differentiation and maturation of osteo-
clasts [4], as well as activity of osteoclasts [5]. By contrast,
mature osteoblasts produce bone matrix (collagen syn-
thesis and mineralization) [6]. Thus, the control of osteo-
blast differentiation is critical in the management of bone
diseases.
In recent years, much interest emerged for the bone
marrow-derived mesenchymal stromal cells (MSC) due
to their ability to self-renew, proliferate and differentiate
into a variety of cell types of mesodermal, endodermal
and ectodermal origins [7]. There are no specific markers
of MSC but these cells can be selected on the basis of a
complex immunophenotype, comprising the differential
expression of cell surface molecules (CD29, CD73, CD90,
CD105 and CD166), and of markers of hematopoietic
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stem cells (CD34, CD45) and endothelial cells (CD31) [8].
MSC exhibit various phenotypic characteristics of osteo-
blasts and can be grown in culture to differentiate into
mature osteoblasts able to form mineralized bone nod-
ules [9,10]. Recent studies have demonstrated successful
osteogenic differentiation of MSC following treatment
with bone morphogenetic proteins (BMP)-2,-4,-6 [11],
parathyroid hormone (PTH) plus vitamin D3 [12], trans-
forming growth factor beta 1 (TGFβ1) [13], estrogens
[14], and also oxysterols [15]. On the other hand, the
combination of dexamethasone, ascorbic acid and β-glyc-
erophosphate (DAG) remains the most widely used tool
to induce differentiation of MSC into osteoblasts [16], but
specific markers of the osteoblast lineage, especially dur-
ing the early stages of differentiation, remain to be uncov-
ered.
The proto-oncogene Src is a member of the Src family
kinases (SFK) and has important roles in physiological
and pathological processes such as cell survival, differen-
tiation, tumorigenesis and inflammation [17]. Src kinase
is regulated by growth factors, cytokines, cell adhesion,
and antigen receptor activation [18]. It is generally main-
tained in an inactive conformation by phosphorylation at
527Tyr. The dephosphorylation of this residue by phos-
phatases leads to intramolecular autophosphorylation at
416Tyr, promoting the kinase activity [19]. Src signaling
coordinates both osteoclast and osteoblast activities [20].
Recent studies have reported that Src kinase plays a posi-
tive role in osteoclast survival and resorbing activity,
including cytoplasm polarization and ruffled border for-
mation [21]. On the other hand, Src may negatively regu-
late osteoblast maturation through a mechanism where
the cytoplasmic shuttling Yes-associated protein (YAP) is
recruited on the runt-related transcription factor 2
(Runx2) nuclear domains to inhibit expression of Runx2
regulated genes [22]. Thus, Src kinase is essential for
osteoclast activation and osteoblast inhibition [20,23],
and stands out as a promising therapeutic target for the
prevention and the treatment of bone loss.
Dasatinib (BMS-354825) is a new dual Src/Bcr-Abl
tyrosine kinase inhibitor. It was originally developed for
the treatment of patients with chronic myeloid leukemia
(CML) associated with a reciprocal translocation
between chromosomes 9 and 22 that results in the forma-
tion of the Philadelphia chromosome and constitutively
active tyrosine kinase Bcr-Abl [24]. It has recently been
used for the treatment of imatinib-resistant CML [25].
Besides CML, dasatinib, by acting as a Src kinase inhibi-
tor, has shown promising results in preclinical studies in
various solid tumors. A recent study using non-small cell
lung cancer and head and neck squamous cell carcinoma
cells has shown that it can inhibit cell migration and inva-
sion, arrest cell cycle, and induce apoptosis [26]. In pros-
tate cancer cells, dasatinib was reported to block the
kinase activity of Src and inhibit tumor cells adhesion,
migration and invasion [27]. It is also able to decrease
tumor size and reduce the metastatic potential of pancre-
atic cancer cells in an orthotopic nude mouse model [28].
In addition, very recent data revealed that dasatinib
strongly promoted differentiation of primary mouse
osteoblasts isolated from mouse calvaria [29].
In the present study, we evaluated the effects of the Src
inhibitor dasatinib on osteogenesis using an in vitro
model of osteoblast differentiation comprising human
bone marrow-derived MSC treated or not with DAG. To
this aim, we first identified each stage of the differentia-
tion using a panel of specific markers, and then, we exam-
ined the effects of dasatinib on these markers.
Methods
Selection and culture of human bone marrow-derived 
mesenchymal stromal cells
Bone marrow was harvested from the sternum of healthy
volunteer donors (n = 7) and from the iliac crest of
donors of bone marrow for transplantion (n = 3). The
mean age of the donors was 25 years (range 5-55).
Informed consent was obtained from all donors. The eth-
ics committee of our Institution approved the use of the
tissue material for this study.
Mononuclear cells (MNC) were isolated by density gra-
dient centrifugation (Linfosep, Biomedics, Madrid,
Spain) and washed in HBSS medium (BioWhittaker,
Walkersville, MD). MNC were seeded at 5 × 106 cells/cm2
in alpha-minimum essential medium (α-MEM, BioWhit-
taker) supplemented with 15% FBS, 2 mM L-glutamine,
0.5% antibiotic/antimycotic solution (all from Gibco-
BRL, Life Technologies, Merelbeke, Belgium). Cells were
incubated at 37°C in a humidified 95% air and 5% CO2
atmosphere, cultured up to 80% confluence, and then
trypsinized (trypsin-EDTA solution, Gibco-BRL), centri-
fuged, and replated at a density of 200 cells/cm2 for all
subsequent passages. All experiments were performed
with cells after the second or the third passage.
Colony Forming Unit (CFU-F) assay
CFU-F assay was used to evaluate the number of mesen-
chymal progenitors in fresh bone marrow and after each
passage. 105 MNC or 5,000 cells obtained after each pas-
sage were incubated in Petri dishes in a complete α-MEM
medium. Ten days later, fibroblastic colonies with more
than 50 cells were counted under light microscopy after a
May Grunwald Giemsa coloration (Merck, Darmstadt,
Germany).
Flow cytometry analysis
MSC phenotype was evaluated after each passage by the
expression of CD31 (Immunotech, Marseille, France),
CD34 (BD Biosciences Pharmingen, San Diego, CA),Id Boufker et al. BMC Cancer 2010, 10:298
http://www.biomedcentral.com/1471-2407/10/298
Page 3 of 13
CD29 (Immunotech), CD45 and HLA-DR (Exalpha Bio-
logicals, Maynard, MA), CD166 (DakoCytomation Den-
mark A/S, Glostrup, Denmark), CD73 (BD Biosciences
Pharmingen) and CD105 (RD Systems, Minneapolis,
MN). Cells were incubated for 30 min at room tempera-
ture with primary PE- (phycoerythrine) or FITC- (fluo-
resceine isothiocyanate) conjugated antibodies. Flow
cytometry was performed using a Coulter EPICS XL
(Beckman-Coulter, Miami, FL); 5,000 events for each
sample were recorded.
Induction of osteogenic differentiation
MSC were seeded at 2,500 cells/cm2 in 24-well dishes (for
calcium & ALP assays) or in Petri culture plates (for RT-
PCR) and cultured in α-MEM supplemented with 15%
FBS up to confluence. Osteoblastic differentiation of
MSC was induced by incubation with 10-7 M dexametha-
sone (Aacidexam®, Aaciphar, Brussels, Belgium), 6 × 10-5
M ascorbic acid (Sigma, St Louis, MO) and 10-2 M β-glyc-
erophosphate (Sigma) (=DAG) [16] for up to 3 weeks.
Dasatinib, provided by Bristol Myers Squibb (Princeton,
NJ), was solubilized in dimethyl sulfoxide (DMSO) (stock
solution 10-1 M) and used at 10-8 M alone or in combina-
tion with DAG (as specified in Results). E804 (indirubin-
3'-(2,3-dihydroxypropyl)oximether, Alexis Biochemicals,
Enzo Life Sciences BVBA, Zandhoven, Belgium), a spe-
cific Src inhibitor, was solubilized in DMSO (stock solu-
tion 10-2 M) and used at 10-7 M alone or in combination
with DAG. The osteogenic medium was changed weekly
and experiments were stopped after 7, 14 or 21 days to
assess the osteoblastic phenotype of MSC. Osteogenic
differentiation was monitored by mineralization assay,
alkaline phosphatase activity measurement, osteoblast-
related gene expression determination, and RANKL/
OPN ratio ELISA evaluation.
Quantitative determination of calcium accumulation
To evaluate calcium deposition, the matrix was deminer-
alized by addition of 500 μl of 0.6 N HCl during an over-
night incubation at 37°C. Solutions were then collected
and centrifuged at 2,000 × g for 5 min. Calcium concen-
tration in the supernatant was determined by colorimetry
(QuantiChrom Calcium Assays Kit, BioAssay Systems,
Hayward, CA) as described by the manufacturer. Briefly,
5 μl samples were combined with 200 μl calcium reagent
and incubated for 5 min at room temperature. The absor-
bance was measured immediately after incubation at 610
nm using a plate reader (Organon Teknika Cappel Prod-
ucts, West Chester, PA).
Quantitative analysis of alkaline phosphatase activity
ALP activity was determined using the LabAssay™ ALP
(Wako Chemicals Gmbh, Neus, Germany), according to
the manufacturer's recommendations. This measurement
consists of the determination of the quantity of p-nitrop-
henol released from the substrate. The cell layers were
lysed with 100 μl of ice-cold 0.1% Triton X-100 in PBS.
Samples were then frozen and thawed twice, and the cell
lysates were collected. Samples (20 μl) were combined
with 100 μl ALP reagent and the activity was measured
after an incubation of 15 min at 37°C. The absorbance
was measured immediately at 405 nm and the amount of
p-nitrophenol was determined by comparison with a
standard curve. ALP activity (U, μmol p-nitrophenol
released per min) was normalized to the number of cells
evaluated by the trypan blue dye exclusion assay.
Semi-quantitative RT-PCR assay
Total RNA from MSC cultured in Petri plates was
extracted by the Tripure method (Roche Diagnostics,
Indianapolis, IN). The samples (1 μg RNA) were treated
by DNAse (Invitrogen Life Technologies, Merelbeek, Bel-
gium) at 37°C for 30 min in a final volume of 10 μl con-
taining 1 μl DNAse, 10 × buffer and 1 U DNAse RQI. The
reverse transcription was performed with 1 μg DNAse-
treated RNA using the M-MLV reverse transcriptase
(Invitrogen Life Technologies) in a final volume of 20 μl
containing 4 μl first-strand buffer, 10-2 M DTT, 1 μM each
of dNTP, 50 URNase inhibitor, and 100 U M-MLV reverse
transcriptase, leading to the production of cDNA. Five ng
cDNA were used for PCR reaction in a final volume of 50
μl containing 25 μl multiplex PCR mix and 200 nmol for-
ward and reverse primers (Sigma-Genosys, Pampisford
Cambs, U.K.) (see list in Table 1). After the activation step
(95°C for 15 min), each cycle consisted of denaturation at
94°C for 30 sec, annealing at 60°C for 90 sec, extension at
72°C for 90 sec and elongation at 72°C for 10 min. After
the optimal number of cycles determined for each primer
set, PCR products were separated by electrophoresis on
2% (w/v) agarose gel and were visualized by ethidium
bromide staining. Gels were scanned with FLA-5000
imaging system (Fujifilm, Tokyo, Japan) and Image
Reader software (Raytest®, Straubenhardt, Germany).
Band intensities were quantified using AIDA®  Image
Analyser 3.45 software (Raytest®) and normalized against
β-actin mRNA used as an internal control.
Real-time quantitative PCR assay
Messenger RNA expressions of relevant osteoblast-
related markers (RANKL, OPG, BSP, OPN) were quanti-
fied by RTqPCR using SYBR® Green dye (SYBR® Green
PCR Master Mix, Applied Biosystems, Foster City, CA)
and sequence-specific primers (Table 2). Total RNA from
control and treated cells was isolated using Tripure
method (Roche Diagnostics). Reverse transcription was
performed using 1 μg total RNA and the reverse tran-
scription system (Promega, Madison, WI). The amplifica-
tion was performed in an ABI PRISM® 7900 SequenceId Boufker et al. BMC Cancer 2010, 10:298
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Detection System (Applied Biosystems) with 40 cycles of
a two-step PCR (95°C for 15 sec and 60°C for 60 sec) after
an initial activation step (95°C for 10 min). Melting
curves from 60°C to 99°C were assessed to evaluate speci-
ficity. Serial dilutions of purified amplicons served to gen-
erate standard melting curves. Relative quantification
was calculated by normalizing the test crossing thresh-
olds (Ct) with the β-actin amplified control Ct.
Cell proliferation assay
Cell proliferation was assessed by a colorimetric assay
based on the cleavage of the tetrazolium salt WST-1 to a
formazan-class dye by the mitochondrial succinate-tetra-
zolium reductase in viable cells. Briefly, MSC were
seeded in 96-well plates (density 1,000 cells/well) in com-
plete culture medium and cultured for 24 hours. Cells
were then exposed to increasing concentrations of dasat-
Table 1: Primers used for semi-quantitative RT-PCR evaluation of RNA of osteoblast-related genes and housekeeping 
gene.
Transcript name RT-PCR primer set (5'-3') Product length
β-actin Forward
Reverse
tgacggggtcaccacactgtgcccatcta
ctagaagcatttgcggtggacgatggaggg
610
ALP Forward
Reverse
cagaagctcaacaccaacg
ccagcaagaagaagcctttg
815
BMP2 Forward
Reverse
cccacttggaggagaaacaa
acgtctgaacaatggcatga
351
BSP Forward
Reverse
atggcctgtgctttctcaat
ccgtttatgccttgttcgtt
497
Runx2 Forward
Reverse
aagaaggacagacagaagc
aggtggcagtgtcatcatct
428
COL-I Forward
Reverse
agtgctagacatgctcagct
ttcaccatctctgcctgcgg
173
OPG Forward
Reverse
tgcagtacgtcaagcaggag
gtgtcttggtcgccattttt
754
OPN Forward
Reverse
ctaggcatcacctgtgccatacc
cagtgaccagttcatcagattcatc
395
OSN Forward
Reverse
gtgcagaggaaaccgaagag
tcattgctgcacaccttctc
172
OSX Forward
Reverse
ggcacaaagaagccgtactc
gccttgtaccaggagccata
296
PTHr Forward
Reverse
aggaacagatcttcctgctgca
tgcatgtggatgtagttgcgcgt
521
RANKL Forward
Reverse
agagcgcagatggatcctaa
ttccttttgcacagctcctt
180
Table 2: Primers used for real-time quantitative RT-PCR evaluation of RNA of RANKL, OPG, BSP, OPN and β-actin.
Transcript name RT-PCR primer set (5'-3') Product length
β-actin Forward
Reverse
ctggcacccagcacaatg
ccgatccacacggagtacttg
68
BSP Forward
Reverse
tacacgggcgtcaatgaata
aggttccccgttctcacttt
63
OPG Forward
Reverse
ggcaacacagctcacaagaa
cgctgttttcacagaggtca
117
OPN Forward
Reverse
ttgcagtgatttgcttttgc
gccacagcatctgggtattt
115
RANKL Forward
Reverse
agagcgcagatggatcctaa
ttccttttgcacagctcctt
180Id Boufker et al. BMC Cancer 2010, 10:298
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inib or vehicle, in presence or not of DAG, for 3, 7 or 10
days as described in "Results". Then, the Cell Proliferation
Reagent WST-1 (Roche Molecular Biochemicals, Man-
nheim, Germany) was added to the plate, and the cells
were cultured for 2 additional hours. The quantity of for-
mazan dye, directly related to the number of metaboli-
cally active cells, was quantified by measuring the
absorbance at 450 nm with a multiwell spectrophotome-
ter (Organon Teknica, Austria). Blank wells lacked cells
and drugs.
Western blotting
Control and dasatinib-treated MSC (cultured in Petri
plates) were lysed using detergent cocktail (M-PER Mam-
malian Extraction Buffer) supplemented with protease
inhibitors (Halt Protease Inhibitor Cocktail) and phos-
phatase inhibitors (Halt Phosphatase Inhibitor Cocktail)
(all from Pierce, Rockford, IL, USA). Protein concentra-
tions were determined by the BCA Protein Assay (Pierce)
using bovine serum albumin as standard. Equal amounts
of cell proteins (30 μg) were subjected to 10% SDS-PAGE
and electrotransferred onto nitrocellulose membranes
(Amersham Pharmacia Biotech, Roosendaal, The Nether-
lands). Immunodetections were performed using a rabbit
polyclonal anti-human p-Src (Tyr 419) antibody (1:200)
(Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a
rabbit polyclonal anti-human Src antibody (1:1,000) (Cell
Signaling Technology, Danvers, MA, USA). Peroxidase-
labeled anti-rabbit IgG antibody (1:5,000) (from Amer-
sham Pharmacia Biotech) was used as secondary
reagents. Bound peroxidase activity was revealed using
the SuperSignal® West Pico Chemiluminescent Substrate
(Pierce). Immunostaining signals were digitalized with a
PC-driven LAS-3000 CCD camera (Fujifilm, Tokyo,
Japan), using a software specifically designed for image
acquisition (Image Reader, Raytest®, Straubenhardt, Ger-
many).
Enzyme-linked immunosorbent assay (ELISA)
Measurements of RANKL and OPG in 24-hours condi-
tioned medium of MSC (cultured in Petri plates) exposed
to dasatinib for 3 and 7 days were performed using two
commercially available ELISA kits (ampli-sRANKL
ELISA and Osteoprotegerin ELISA, Biomedica GmbH,
Vienna, Austria) according to the manufacturer's instruc-
t i o n s .  B r i e f l y ,  5 0  μ l  c o n d i t i o n e d  m e d i u m  ( 1  m l  c o r r e -
sponding to 105  cells) or Standards, 50 μl polyclonal
biotinylated antibodies, and 100 μl Assay Buffer were
incubated for 24 hours at 4°C in microtiter plates pre-
coated with human recombinant OPG (for RANKL
detection) or monoclonal anti-OPG antibody (for OPG
detection). The wells were washed with 300 μl Wash Buf-
fer and were incubated with 200 μl Conjugate for 1 hour
at room temperature. Then, the wells were incubated
with Substrate for 20 min at room temperature and the
absorbance was measured using a plate reader (Organon
Teknika Cappel Products) at 450 nm with reference at
620 nm after the addition of 50 μl Stop Solution. Standard
ranges were 0-2 pmol/L for RANKL and 0-30 pmol/L for
OPG. Detection limits were 0.02 pmol/L for RANKL and
0.14 pmol/L for OPG. Data were normalized to total pro-
tein content (BCA Protein Assay, Pierce) and were pre-
sented as RANKL/OPG ratio.
Statistical analysis
Results are expressed as the mean ± the standard error of
the mean (SEM) of independent experiments (one exper-
iment used bone marrow-derived MSC from one single
donor), each performed in duplicate. Statistical analysis
was performed by analysis of variance (ANOVA). Tukey
post hoc test was used for multiple comparisons between
groups. Statistical significance was set at * 0.05, ** 0.01
and *** 0.001. All analyses used SPSS software (Paris,
France).
Results
Isolation and expansion of MSC
MSC cultures were initiated from 20 ml of bone marrow
aspirates obtained from 10 healthy donors. After plating,
cells showed monocyte-like and fibroblast-like morphol-
ogy. During cell expansion, fibroblast-like cells (=MSC)
became progressively predominant and proliferated up to
confluence. To estimate the number of mesenchymal pro-
genitors during expansion, the ability of MNC to form
fibroblastic colonies were assessed using the colony form-
ing unit - fibroblastic assay (CFU-F assay). The mean ±
SEM number of CFU-F obtained from the 10 bone mar-
row samples was 22 ± 6 colonies/106 cells, confirming the
low level of MSC in the bone marrow. After passage 1, the
mean number of CFU-F significantly increased to 18 ± 4
× 104 colonies/106 cells. Importantly, CFU-F efficiency
remained stable throughout the duration of the culture.
In addition, the expression of MSC surface antigens was
evaluated after each passage. Flow cytometry analysis
revealed that the majority of adherent cells were positive
for CD29, CD166, CD105 and CD73, and were negative
for markers of the endothelial lineage CD31, of the
hematopoietic lineage (CD34) and for the leukocyte com-
mon antigen CD45 and HLA-DR (=MHC-II molecule),
confirming the selection of MSC.
Evaluation of matrix mineralization, alkaline phosphatase 
activity and osteoblast-related gene expression in MSC 
exposed to DAG
Calcium deposition was quantified by colorimetric assay
(Fig. 1A). DAG treatment of MSC stimulated calcium
deposition (increased by 6.5 and 12.3-fold compared to
untreated MSC at days 14 and 21, respectively), confirm-Id Boufker et al. BMC Cancer 2010, 10:298
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ing that DAG is able to induce differentiation of MSC into
the osteogenic lineage up to matrix mineralization.
ALP activity was quantified with the LabAssay™ ALP
(Wako Chemicals Gmbh, Neus, Germany). It was signifi-
cantly increased in DAG-treated MSC: it increased at day
7 (by 2.6-fold versus untreated cells at day 0), reached a
maximum at day 14 (7.1-fold) and decreased after 21 days
(2.3-fold) of exposure to DAG (Fig. 1B). These data indi-
cate that enhancement of ALP activity precede matrix
mineralization.
Changes in mRNA levels of osteoblast-related genes
were examined using semi-quatitative RT-PCR during
osteoblastic differentiation of MSC treated with DAG.
We assessed gene expressions of (i) transcription factors
known to be required for bone formation (Runx2, osterix
[OSX]), (ii) hormones and receptors implicated in osteo-
blast activity (PTH receptor [PTHr], bone morphoge-
netic protein-2 [BMP-2], sclerostin [SOST]), (iii)
extracellular matrix proteins and enzymes reflecting
osteoblastic phenotype (type-I collagen [COL-I], bone
sialoprotein [BSP], osteopontin [OPN], osteonectin
[OSN], alkaline phosphatase [ALP]) and (iv) factors con-
trolling osteogenesis (receptor activator of NFκ-B ligand
[RANKL] and osteoprotegerin [OPG]). β-actin was used
as housekeeping gene. The tested genes could be classi-
fied into three groups (Fig. 2). The first group included
the RANKL gene whose expression was high in untreated
cells and fell to lower levels during the whole process of
osteoblast differentiation (Fig. 2A). The second group
was composed of Runx2, COL-I, OSN and OPG genes
whose expressions were already detectable in untreated
MSC and were not significantly modified by DAG treat-
ment (Fig. 2B). These gene markers cannot thus help to
define the osteoblastic stage. The third group comprised
BMP-2, ALP, PTHr, OPN, OSX and BSP genes whose
Figure 1 Quantitative analysis of matrix calcification and alkaline 
phosphatase activity during osteogenic differentiation of MSC. A: 
Calcium content of the extracellular matrix of control cell cultures 
(open bars) and DAG-treated cell cultures (black bars) was determined 
after 7, 14 and 21 days. B: ALP activity in MSC cultured in control (open 
bars) or osteogenic (black bars) medium was measured after 7, 14 and 
21 days. ALP activity (U, μmol p-nitrophenol released per min) was nor-
malized for 105 cells. A, B: Results are presented as mean ± SEM from 5 
independent experiments performed in duplicate; *** p < 0.001 versus 
the corresponding control.
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expressions were not (BSP, OPN and OSX) or weakly
detectable in untreated MSC, but significantly increased
in DAG-treated cells to reach maximal values after 7
(BSP), 14 (BMP-2, ALP) or 21 days (PTHr, OPN, OSX)
(Fig. 2C).
Of note, ALP activity (Fig. 1B) did not reveal compara-
ble changes to the ALP gene (Fig. 2C) during the differen-
tiation process of MSC induced by DAG. Indeed, no or
low ALP activity was measured in undifferentiated MSC
which expressed moderate levels of ALP gene, and ALP
activity was significantly reduced in "late osteoblasts"
which kept a relatively high expression level of ALP gene.
Therefore, due to the specific variations in ALP activity
during MSC differentiation into osteoblasts, we selected
this parameter to characterize the differentiation steps.
Thus, this part of the study allowed us to identify min-
eralization process, ALP activity and expression of
RANKL, BSP and OPN as strong markers of osteoblastic
differentiation of MSC since they were clearly changing
between each stage of the differentiation process (Fig. 3).
This model was further used to test the Src inhibitor
dasatinib on MSC differentiation into osteoblasts.
Effect of dasatinib on MSC proliferation
In order to determine non-toxic dasatinib concentrations
that could be used to perform MSC differentiation assays,
MSC were incubated with increasing concentrations of
dasatinib (from 10-9  to 10-4  M) for 3, 7 or 10 days.
Changes in cell proliferation were measured by WST-1
assay. Dasatinib induced a concentration-dependent
decrease in cell proliferation: it had no effect at the lowest
tested concentrations (10-9 and 10-8 M), had low inhibi-
tory effects between 10-7 and 10-5 M and was clearly toxic
at 10-4  M (Fig. 4A), with morphological evidences of
necrotic cell death (data not shown). Of note, DAG
induced a weak inhibition of cell proliferation, but it did
not change the concentration-related toxicity of dasatinib
in MSC (Fig. 4B). Therefore, 10-8 M dasatinib was identi-
fied as the highest non-toxic concentration to be used in
differentiation assays.
Effect of dasatinib on Src phosphorylation in MSC
The activity of Src was evaluated by the level of Tyr 419
phosphorylation of Src in MSC exposed to 10-8 and 10-7
M dasatinib for 30 min or 24 hours. As shown in Fig. 5A,
Src phosphorylation is significantly decrease in cells
treated by 10-7 M dasatinib for 30 min and in cells incu-
bated with both drug concentrations for 24 hours, con-
firming that Src is a target of dasatinib in MSC.
Importantly, DAG did not affect neither the Src phospho-
rylation nor the inhibition of Src phosphorylation
induced by 10-7 M dasatinib for 24 hours (Fig. 5B), indi-
cating that dasatinib completes the effect of DAG on
MSC differentiation by acting on Src. As positive control,
the Src inhibitor E804 (10-7  M, 24 hours) strongly
decreased the phosphorylation of the tyrosine kinase
(Fig. 5C).
Effect of dasatinib on calcium deposition in MSC
Mineralization of the extracellular matrix by MSC was
determined by colorimetric assays after 7, 14 and 21 days
of culture in control or osteogenic medium, supple-
mented or not with 10-8 M dasatinib (Fig. 6A). Calcium
deposition was very low after 7 days in all culture condi-
tions. Calcification was observed after 14 days in cells
cultured with DAG where dasatinib significantly
increased the mineralization induced by DAG (apparent
synergism). After 21 days, matrix calcification was fur-
ther enhanced in presence of DAG, but dasatinib did not
affect these high levels of calcium deposition. Thus, dasa-
tinib alone was unable to affect matrix mineralization,
but it may accelerate the process of calcification in pres-
ence of DAG.
Effect of dasatinib on alkaline phosphatase activity in MSC
The activity of ALP was evaluated in MSC after 7, 14 and
21 days of culture with or without DAG and 10-8 M dasat-
inib (Fig. 6B). After 7 days, dasatinib alone and DAG
alone did not affect ALP activity, while the combination
of both treatments significantly increased ALP activity
Figure 3 Scheme indicating that a combination of 5 osteoblast-
related parameter levels/activity (Ca++ deposition, ALP activity, 
and RANKL, BSP, OPN gene expression) can be used as an indica-
tor of the stage of MSC differentiation into osteoblasts. Using this 
setting, 4 stages were defined: (i) undifferentiated MSC (=native stage) 
expressed high RANKL levels, but no BSP, no OPN, no ALP and no min-
eralization activity, (ii) osteoprogenitors (=early stage observed after 7 
days of DAG treatment) expressed high BSP, moderate RANKL, moder-
ate OPN levels, but had low ALP and no mineralization activity, (iii) ma-
ture osteoblasts (=intermediate stage reached after 14 days of DAG 
treatment) had a high ALP activity, expressed high BSP, high OPN, 
moderate RANKL levels and had low mineralization activity, and (iv) 
late osteoblasts (=late stage obtained after 21 days of DAG treatment) 
had a high mineralization activity, expressed high BSP, high OPN and 
moderate RANKL levels and had moderate ALP activity.
Mature
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Osteoprogenitors Mesenchymal
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(apparent synergism). At 14 and 21 days, ALP activity was
higher than at 7 days in all culture conditions, and dasat-
inib failed to induce any additional stimulation of ALP
activity over DAG. Hence, dasatinib may increase ALP
activity early in the osteoblastic differentiation process of
MSC. Importantly, the Src inhibitor E804 (10-7 M) simi-
larly potentiated the effect of DAG, increasing ALP activ-
ity after 7 days (Fig. 6C). These data strongly support that
the effect of dasatinib in MSC was mediated through the
inhibition of Src.
Effect of dasatinib on osteoblast-related gene expression in 
MSC
We identified 3 osteoblast-related genes (RANKL, BSP
and OPN) whose levels of expression are informative of
the osteoblastic differentiation status of MSC (see above).
The expression of these genes reflecting MSC differentia-
tion status was assessed by real-time quantitative PCR in
MSC treated or not with DAG and exposed or not to 10-8
M dasatinib (Fig. 7). Dasatinib and DAG, either alone or
in combination, significantly decreased the expression of
RANKL after 7 days of culture, but dasatinib did not
induce additional effects on RANKL expression after 14
and 21 days. However, OPG mRNA expression did not
significantly change during osteoblastic differentiation of
MSC, indicating that the RANKL/OPG ratio variations
paralleled the changes in RANKL. On the other hand,
dasatinib alone significantly increased the expression of
BSP after 21 days, while it enhanced OPN expression
after 14 and 21 days. In addition, dasatinib also increased
the DAG-induced upregulation of BSP after 14 days and
of OPN after 14 and 21 days. Therefore, dasatinib was
able to modulate the expression of osteoblast-related
genes in a time-dependent manner, and it may also
potentiate the effects of DAG on BSP and OPN expres-
sions.
Figure 4 Proliferation rate of MSC exposed to dasatinib alone or 
in combination with DAG. A: Cells were treated for 3, 7 and 10 days 
with increasing concentrations of the drug (10-9 - 10-4 M) or vehicle 
(Control) in complete culture medium. B: Cells were exposed to in-
creasing concentrations of the dasatinib (10-9 - 10-4 M) or vehicle (Con-
trol) in complete culture medium supplemented or not with DAG for 
3, 7 and 10 days. A, B: Cell proliferation was determined by a colorimet-
ric assay using the Cell Proliferation Reagent WST-1. The results are pre-
sented as mean ± SEM from 4 independent experiments performed in 
duplicate; * p < 0.05 versus the corresponding control.
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Figure 5 Effect of dasatinib or E804 on Src phosphorylation. A: 
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Immunodetections were performed using p-Src (Tyr 419) or Src anti-
bodies, secondary antibodies and chemiluminescent substrate. Repre-
sentative results from 2 independent experiments.
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Effect of dasatinib on RANKL/OPG ratio in MSC
To further investigate the effects of dasatinib on the
expression of RANKL at protein level in short-term
experiments, RANKL protein was evaluated by ELISA in
24-hours conditioned medium of MSC exposed to 10-8
and 10-7 M dasatinib, in absence of DAG, for 3 and 7 days.
OPG protein was also measured by ELISA in the same
samples and results are presented as RANKL/OPG ratio
(Fig. 8). Data indicated that both concentrations of dasat-
inib significantly decreased the RANKL/OPG ratio at
days 3 and 7, resulting from a weak and not significant
increase in OPG expression (e.g. 1.7 fold, 10-7 M drug, day
3) and a dramatic decrease in RANKL expression (e.g. 9
fold, 10-7 M drug, day 3). This result strongly confirms
our above observation at mRNA level.
Discussion
We assessed the effects of the Src inhibitor dasatinib on
the osteogenic differentiation of bone marrow-derived
mesenchymal stromal cells (MSC) treated or not with a
combination of dexamethasone, ascorbic acid and β-glyc-
erophosphate (DAG).
Firstly, we have searched for the most informative
markers of osteogenic differentiation of MSC induced by
DAG and found a set of 5 markers (mineralization, ALP
activity and expression of RANKL, BSP and OPN) that
best characterize the 4 stages of osteoblast differentia-
tion: native stage (undifferentiated MSC), early stage
(osteoprogenitors), intermediate stage (mature osteo-
blasts), and late stage (late osteoblasts). Of note, many
genes related to the osteoblastic phenotype or activity
have been previously used to define the osteoblastic sta-
tus of different cellular types [30,31]. However, in our
model, we found that the expression of several of them,
Figure 6 Quantitative determination of matrix calcification and 
alkaline phosphatase activity in MSC exposed to dasatinib or 
E804. A: Matrix calcium content of untreated MSC (Control), and cells 
cultured with 10-8 M dasatinib, DAG or a combination of both treat-
ments, was assessed after 7, 14 and 21 days. B: ALP activity in MSC cul-
tured in control medium supplemented or not with 10-8 M dasatinib 
and/or DAG was measured after 7, 14 and 21 days. ALP activity (U, μmol 
p-nitrophenol released per min) was normalized. C: ALP activity in MSC 
exposed to 10-7 M E804 and/or DAG for 7, 14 and 21 days. ALP activity 
(U, μmol p-nitrophenol released per min) was normalized normalized 
for 105 cells. A, B, C: Results are presented as mean ± SEM from 4 inde-
pendent experiments performed in duplicate; * p < 0.05, ** p < 0.01 
and *** p < 0.001 versus the corresponding control, and comparing 
DAG versus Dasatinib+DAG or versus E804+DAG.
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dent experiments performed in duplicate; * p < 0.05, ** p < 0.01 and 
*** p < 0.001 versus the corresponding control, and comparing DAG 
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notably Runx2, COL-I, OSN and OPG, was already pres-
ent in DAG-untreated MSC and remained unchanged
during osteoblastic differentiation, while others have
reported that the expression of Runx2 and COL-I
increased along the osteoblast differentiation [32]. This
divergence can be explained by the fact that MSC prepa-
rations may contain multidifferentiated cells, which
express both immature and mature proteins of different
tissues [33,34]. In addition, recent reports indicate that
the phosphorylation level but not the expression level of
Runx2 is related to the differentiation status of osteo-
blasts [35]. Therefore, the expression of these genes
should be considered rather as a weak indicator of MSC
differentiation into osteoblasts. Interestingly and in
accordance with previous observations [36,37], ALP
activity and gene expression increased during MSC dif-
ferentiation into osteoblasts. However, we found that
ALP activity and gene expression did not fully correlate;
ALP activity is probably more reliable to the mineraliza-
tion process. Indeed, in undifferentiated MSC and late
osteoblasts, ALP activity was, respectively, very low and
significantly downregulated, while ALP mRNA was
expressed at high levels. These data indicate that ALP
activity is more informative than ALP gene expression as
a marker of MSC differentiation.
Based on our selection of markers, we have evaluated
the effects of the Src inhibitor dasatinib on the differenti-
ation of MSC into osteoblasts. Our interest in Src inhibi-
tors stems from a recent study showing that the
differentiation of the MC3T3-E1 pre-osteoblasts was
accompanied by a decrease in phosphorylation of the
activator site (416Tyr) of Src and an increase in phospho-
rylation of its inhibitor site (527Tyr) [38]. This indicates
that the post-translational inhibition of Src is associated
with the activation of osteoblast differentiation. More-
o v e r ,  t a r g e t e d  d i s r u p t i o n  o f  S r c  g e n e  i n  m i c e  l e a d s  t o
osteopetrosis [39], and osteoblasts isolated from Src-/-
mice exhibit accelerated differentiation and elevated lev-
els of osteoblast-related markers [40]. Taken together,
these data suggest that Src inhibition may stimulate
osteoblast differentiation. To validate that Src was tar-
geted by dasatinib in MSC, we confirmed that dasatinib
inhibits the phosphorylation of the activator site of Src.
We also showed that the specific Src inhibitor E804 stim-
ulated osteoblast differentiation as it increased ALP
activity in MSC exposed to DAG. By contrast, mice defi-
cient in Abl, another potent target of dasatinib, are osteo-
porotic and have defects in osteoblast maturation [41],
excluding a positive role of Abl inhibition by dasatinib in
the differentiation of MSC into osteoblasts. We also con-
sidered other targets of dasatinib, namely platelet-derived
growth factor receptor (PDGFR) [42] and cKIT/CD117
[43]. The role of PDGFR in the osteoblastic differentia-
tion of MSC remains, however, controversial [44,45], and
new data clearly demonstrated that PDGFR signaling is
not involved in osteogenic differentiation of human MSC,
while it affects MSC proliferation [46]. On the other
hand, we did not detect cKIT in MSC (data not shown,
Western blotting using mouse mAb cKIT (Ab81) from
Cell Signaling Technology, LND1 melanoma cell line as
positive control), confirming previous observations [47].
Altogether, these data indicate that Src is the most rele-
vant dasatinib target involved in the process of osteoblas-
tic differentiation of MSC.
In this study, we found that dasatinib promoted time-
dependent changes in osteoblast-related markers in
MSC. These changes matched the ones induced by DAG
and corresponded to the progressive differentiation of
MSC into osteoblasts (see Fig. 3). Indeed, we docu-
mented that dasatinib, in combination with DAG,
increased ALP activity after 7 days, and consequently,
speeded up calcium deposition after 14 days without
exceeding the maximum levels reached with DAG alone,
and that it increased the expression of BSP and OPN,
mainly in the late stage of MSC differentiation. Thus,
dasatinib was able to stimulate each stage of the differen-
tiation of MSC into osteoblasts. Importantly, our experi-
ments were performed with a non-toxic but effective
concentration of dasatinib (10-8 M) able to inhibit Src
kinase activity (inhibition of Src phosphorylation) in
accordance with a previous report showing inhibition of
the kinase activity of purified Src protein with an IC50 of
3 × 10-9 M [27]. Altogether, our data, added to previous
Figure 8 Evaluation of RANKL/OPG ratio by ELISA in conditioned 
medium of MSC exposed to dasatinib. Cells were treated or not with 
10-8 and 10-7 M dasatinib in the absence of DAG for 3 and 7 days. 24-
hours conditioned medium were collected at the end of the treatment 
time. RANKL and OPG protein levels were measured by ELISA in condi-
tioned medium (1 ml/105 cells) and normalized to total protein con-
tent. Data are presented as RANKL/OPG ratio (mean ± SEM from 4 
independent experiments). *** p < 0.001 versus the corresponding 
control.
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studies from other groups [20,22,23,27], strongly support
that Src kinase activity is the main target for dasatinib in
MSC differentiation process. Interestingly, a very recent
study revealed that dasatinib strongly enhanced differen-
tiation of primary mouse osteoblasts isolated from mouse
calvaria (stimulation of ALP activity, osteocalcin secre-
tion, matrix mineralization) [29]. The authors showed
that among the Src family kinases, only Src was activated
at a high level in this model, and that 419Tyr-Src phospho-
rylation was inhibited by dasatinib. Moreover, knock-
down of Src by lenti-shRNA in osteoblasts enhanced
their differentiation, suggesting that dasatinib stimulated
osteoblast differentiation through the inhibition of Src.
Of note, the authors also reported that osteoblast differ-
entiation by dasatinib could be mediated through the
inhibition of Abl, however, they found that Abl was
expressed at a low level in osteoblasts, suggesting a lim-
ited impact.
In the other hand, we observed that dasatinib alone was
a b l e  t o  d e c r e a s e  RA N KL  m R N A  e x p r e s s i o n  a s  w e l l  a s
RANKL protein released in culture medium (decrease in
RANKL/OPG ratio) in undifferentiated MSC (no DAG
induction) cultured up to 7 days, suggesting a possible
indirect inhibitory effect on osteoclastogenesis and, con-
sequently, on bone resorption. In this context, recent
studies reported that tyrosine kinase inhibitors are effec-
tive in inhibiting the differentiation and activity of human
osteoclasts [48], and in preventing bone loss in animal
models [17]. Thus, our data indicate that, in addition to
its previously reported direct inhibitory effects on the
osteoclast formation and activity [49,50], dasatinib may
also act indirectly on osteoclasts through the modulation
of RANKL expression in osteoblasts.
Furthermore, as far as the bone loss associated with
metastases is concerned, recent preclinical and clinical
studies indicated that dasatinib could potentially have
inhibitory effects both on osteoclasts and tumor cells.
Indeed, dasatinib decreased the osteolysis induced by
prostate cancer cells injected into tibiae of SCID mice and
inhibited the growth of cancer cells [51], while it reduced
the expression of markers of bone resorption in patients
with advanced castration-resistant prostate cancer [52].
Thus, our findings complete these observations by dem-
onstrating a direct effect of dasatinib on osteoblasts,
which could further contribute to the disruption of the
vicious circle established between bone cells and tumor
cells.
Our data also suggest that patients with bone loss could
benefit from dasatinib therapy in accordance with critical
findings using imatinib, another tyrosine kinase inhibitor
currently used in chronic myeloid leukemia (CML).
Indeed, short-term imatinib treatment increased OPG/
RANKL ratio and osteocalcin levels in serum of CML
patients [53], while long-term (> 2 years) imatinib therapy
promoted bone formation [54] and increased bone min-
eral density (cortical bone mineralization) [55].
Conclusions
Our study reports an original dual effect of dasatinib on
MSC at non toxic concentrations: (i) it is able to signifi-
cantly speed up the osteogenic differentiation of MSC,
and (ii) it can inhibit RANKL expression in undifferenti-
ated MSC (no DAG induction) thus preventing osteoclast
activation. This dual effect on osteoblasts, on top of its
direct activity on osteoclasts as well as on tumor cells,
may provide a therapeutic benefit in patients with dis-
eases leading to bone loss, such as osteoporosis, tumor-
induced osteolysis, and therapy-induced bone loss.
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